Grace Therapeutics, Stock Performance
| GRCE Stock | 3.58 0.32 8.21% |
On a scale of 0 to 100, Grace Therapeutics, holds a performance score of 9. The company retains a Market Volatility (i.e., Beta) of 0.049, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Grace Therapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Grace Therapeutics, is expected to be smaller as well. Please check Grace Therapeutics,'s sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to make a quick decision on whether Grace Therapeutics,'s current trending patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Grace Therapeutics, are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental indicators, Grace Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (8.21) | Five Day Return (12.90) | Year To Date Return 18.94 | Ten Year Return 18.94 | All Time Return 18.94 |
1 | Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - StockTitan | 10/25/2024 |
2 | GRCE - Grace Therapeutics, Inc. Latest Stock News Market Updates - StockTitan | 10/30/2024 |
3 | Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update | 11/13/2024 |
4 | GRCE Total Inventories 0.00 Mil - GuruFocus.com | 11/20/2024 |
5 | GRCE aSAH KOL Summary | 12/11/2024 |
| Begin Period Cash Flow | 27.9 M |
Grace |
Grace Therapeutics, Relative Risk vs. Return Landscape
If you would invest 258.00 in Grace Therapeutics, on September 16, 2024 and sell it today you would earn a total of 100.00 from holding Grace Therapeutics, or generate 38.76% return on investment over 90 days. Grace Therapeutics, is currently generating 0.6254% in daily expected returns and assumes 5.0768% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Grace, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Grace Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Grace Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Grace Therapeutics,, and traders can use it to determine the average amount a Grace Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1232
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GRCE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.08 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.63 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Grace Therapeutics, is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Grace Therapeutics, by adding it to a well-diversified portfolio.
Grace Therapeutics, Fundamentals Growth
Grace Stock prices reflect investors' perceptions of the future prospects and financial health of Grace Therapeutics,, and Grace Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Grace Stock performance.
| Net Income | (12.85 M) | ||||
| Total Debt | 11.56 M | ||||
| Cash Flow From Operations | (12.33 M) | ||||
| Total Asset | 73.3 M | ||||
| Retained Earnings | (211.12 M) | ||||
About Grace Therapeutics, Performance
By analyzing Grace Therapeutics,'s fundamental ratios, stakeholders can gain valuable insights into Grace Therapeutics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Grace Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Grace Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Grace Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Grace Therapeutics, performance evaluation
Checking the ongoing alerts about Grace Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Grace Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Grace Therapeutics, is way too risky over 90 days horizon | |
| Grace Therapeutics, appears to be risky and price may revert if volatility continues | |
| Grace Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Grace Therapeutics, was previously known as Acasti Pharma and was traded on NASDAQ Exchange under the symbol ACST. | |
| Net Loss for the year was (12.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Grace Therapeutics, generates negative cash flow from operations | |
| Grace Therapeutics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: GRCE aSAH KOL Summary |
- Analyzing Grace Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Grace Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Grace Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Grace Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Grace Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Grace Therapeutics,'s stock. These opinions can provide insight into Grace Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Grace Stock analysis
When running Grace Therapeutics,'s price analysis, check to measure Grace Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grace Therapeutics, is operating at the current time. Most of Grace Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Grace Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grace Therapeutics,'s price. Additionally, you may evaluate how the addition of Grace Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |